<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5958">
  <stage>Registered</stage>
  <submitdate>8/01/2016</submitdate>
  <approvaldate>8/01/2016</approvaldate>
  <nctid>NCT02655822</nctid>
  <trial_identification>
    <studytitle>Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers</studytitle>
    <scientifictitle>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CPI-444-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <healthcondition>Malignant Melanoma</healthcondition>
    <healthcondition>Renal Cell Cancer</healthcondition>
    <healthcondition>Triple Negative Breast Cancer</healthcondition>
    <healthcondition>Colorectal Cancer</healthcondition>
    <healthcondition>Bladder Cancer</healthcondition>
    <healthcondition>Metastatic Castration Resistant Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CPI-444
Treatment: drugs - CPI-444
Treatment: drugs - CPI-444
Treatment: drugs - CPI-444 + atezolizumab

Experimental: Cohort 1 - CPI-444

Experimental: Cohort 2 - CPI-444

Experimental: Cohort 3 - CPI-444

Experimental: Cohort 4 - CPI-444 + atezolizumab


Treatment: drugs: CPI-444
100 mg orally twice daily for the first 14 days of each 28-day cycle.

Treatment: drugs: CPI-444
100 mg orally twice daily for 28 days of each 28-day cycle.

Treatment: drugs: CPI-444
200 mg orally once daily for the first 14 days of each 28-day cycle.

Treatment: drugs: CPI-444 + atezolizumab
CPI-444 orally in combination with atezolizumab intravenously.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dose-limiting toxicities (DLTs) of CPI-444 as a single agent and in combination with atezolizumab</outcome>
      <timepoint>28 days following first administration of CPI-444</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Objective response rate per RECIST v1.1 criteria of CPI-444 as a single agent and in combination with atezolizumab</outcome>
      <timepoint>From start of treatment to end of treatment, up to 24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of CPI-444 as a single agent and in combination with atezolizumab</outcome>
      <timepoint>Continuously, up to 24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean and median Area under the curve (AUC) of CPI-444</outcome>
      <timepoint>Day 14 of Cycle 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean and median Maximum concentration (Cmax) of CPI-444</outcome>
      <timepoint>Day 14 of Cycle 1</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

          2. Documented incurable cancer with one of the following histologies: non-small cell lung
             cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
             colorectal cancer with microsatellite instability (MSI), bladder cancer, and
             metastatic castration resistant prostate cancer.

          3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
             1.1).

          4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
             progressing disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. History of severe hypersensitivity reaction to monoclonal antibodies.

          2. Any active autoimmune disease or a documented history of serious autoimmune disease
             within the past 5 years requiring immunosuppressive therapy.

          3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

          4. The use of any investigational medication or device in the 30 days prior to screening
             and throughout the study is prohibited.

          5. If a patient is currently receiving denosumab, this must be discontinued prior to
             enrollment. Substitution with biphosphonates are acceptable.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>534</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Chris O'Brien Lifehouse - Camperdown</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>Cabrini Hospital Malvern - Malvern</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Corvus Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genentech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small
      molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune
      system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as
      a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid
      tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the
      anti-tumor activity of T cells and other immune cells.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02655822</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A Nguyen</name>
      <address>Corvus Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>